Monitor for any subsequent announcements regarding a replacement for the CEO of API and Services, as the role is critical to the company's active pharmaceutical ingredients and services segment. The long notice period suggests an orderly transition, reducing near-term disruption risk.
RDY drugs
RDY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Aug 13 $12.42entry
- T+1 · 3mo ago −1.21%α −1.01% · $12.27
- T+5 · 3mo ago −2.50%α −0.53% · $12.11
- T+20 · due 2mo ago Pending
- T+60 · due 11d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Laboratories filed a 6-K disclosing the resignation of Mr. Deepak Sapra, CEO of API and Services and Senior Management Personnel, effective November 12, 2026, to pursue opportunities outside the company. This is a routine senior management departure with a standard notice period, and no financial impact or strategic shift is indicated.
Key Facts
- Mr. Deepak Sapra resigned as CEO, API and Services and Senior Management Personnel.
- Resignation effective from close of business on November 12, 2026.
- He will remain with the company until the effective date to ensure a smooth transition.
- He served at Dr. Reddy's for over 23 years since 2003.
- Reason cited: to pursue opportunities outside the company.
Financial Impact
No financial impact disclosed; routine management change.
Risk Factors
- Potential operational disruption if a suitable replacement is not identified before the effective date.
- Loss of institutional knowledge from a 23-year veteran in a key business segment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000568 |
| Document: 0001575872-26-000568-index.html | 0001575872-26-000568 |
| Document: 0001575872-26-000568.txt | 0001575872-26-000568 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers